-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Apellis Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2021 to Q2 2024.
- Apellis Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $114K, a 41.2% decline year-over-year.
- Apellis Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $1.94M.
- Apellis Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $2.13M, a 219% increase from 2022.
- Apellis Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $669K, a 90.1% increase from 2021.
- Apellis Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $352K, a 80.9% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)